home / stock / imrx / imrx articles
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084...
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterati...
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop...
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop ...
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop ...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Immuneering Corporation (NASDAQ:IMRX) on beh...
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstra...
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicine...
News, Short Squeeze, Breakout and More Instantly...
Immuneering Corporation Company Name:
IMRX Stock Symbol:
NASDAQ Market:
Immuneering Corporation Website:
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies...
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - ...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of...